The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
Abstract
PURPOSE: Guidelines for management of postchemotherapy residual mass in patients with advanced seminoma remain controversial. We sought to characterize independent prognostic factor(s) for persistence of tumor to identify patients with a high risk of residual carcinoma. PATIENTS AND METHODS: One hundred four patients with advanced seminoma were assessed. All had achieved a complete response or partial response with normal markers to induction cisplatin-based chemotherapy and had radiographs available for review. Selected prechemotherapy and postchemotherapy characteristics were compared for patients who had either germ cell tumor histology at surgery or relapsed at the assessed site (defined as site failure) versus those who had only necrosis or fibrosis found at surgery and did not relapse at the assessed site (defined as site nonfailure). RESULTS: At a median follow-up time of 47 months (range, 5 to 153), 94 patients (90%) were designated as site nonfailures and 10 (10%) as site failures. Site failure correlated only with size of the residual mass (< 3 cm or normal v > or = 3 cm; P = .0006). Two of 74 patients (3%) with residual masses less than 3 cm were considered site failures, compared with eight of 30 (27%) with residual masses > or = 3 cm. CONCLUSION: Patients with advanced seminoma who have normal radiographs or residual masses less than 3 cm after chemotherapy can be observed without further intervention. The following three options exist for patients with a residual mass > or = 3 cm: observation, radiotherapy, or surgical intervention. We prefer the latter to define response, resect viable tumor when possible, and direct further treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Cited by
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
Schmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S. D., Skakkebaek, N. E., de Wit, R., Fizazi, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh301 · Cited by 510
Horwich, A., Shipley, J., & Huddart, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68305-0 · Cited by 398
Mazumdar, M., & Glassman, J. R. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000115)19:1<113::aid-sim245>3.0.co;2-o · Cited by 367
Self-citationGuidelines on Testicular Cancer
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Horwich, A., Klepp, O., Laguna, M. P., & Pizzocaro, G. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.019 · Cited by 314
Metadata
- Authors
- Puc, H. S., Heelan, R., Mazumdar, M., Herr, H., Scheinfeld, J., Vlamis, V, Bajorin, D. F., Bosl, G. J., Mencel, P., & Motzer, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-02
- Volume
- 14
- Issue
- 2
- Pages
- 454-460
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1838921188
- Cited by
- 199
- References
- 1
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. https://app.cochat.ai/papers/10.1200/jco.1996.14.2.454
- The paper
- Puc, H. S., Heelan, R., Mazumdar, M., Herr, H., Scheinfeld, J., Vlamis, V, Bajorin, D. F., Bosl, G. J., Mencel, P., & Motzer, R. J. (1996). Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1996.14.2.454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.